Search Results - "MAYER, N"

The Wizards of Oz: Towards an Institutional Approach to Elites, Expertise and Command Posts by Zald, Mayer N., Lounsbury, Michael

“…Over the past half century, organizational studies scholarship has increasingly drifted away from addressing broader societal and political issues, as well as…”
Get full text

Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma by Choueiri, Toni K, Fishman, Mayer N, Escudier, Bernard, McDermott, David F, Drake, Charles G, Kluger, Harriet, Stadler, Walter M, Perez-Gracia, Jose Luis, McNeel, Douglas G, Curti, Brendan, Harrison, Michael R, Plimack, Elizabeth R, Appleman, Leonard, Fong, Lawrence, Albiges, Laurence, Cohen, Lewis, Young, Tina C, Chasalow, Scott D, Ross-Macdonald, Petra, Srivastava, Shivani, Jure-Kunkel, Maria, Kurland, John F, Simon, Jason S, Sznol, Mario

“…Nivolumab, an anti-PD-1 immune checkpoint inhibitor, improved overall survival versus everolimus in a phase 3 trial of previously treated patients with…”
Get full text

Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial by Atkins, Michael B, Plimack, Elizabeth R, Puzanov, Igor, Fishman, Mayer N, McDermott, David F, Cho, Daniel C, Vaishampayan, Ulka, George, Saby, Olencki, Thomas E, Tarazi, Jamal C, Rosbrook, Brad, Fernandez, Kathrine C, Lechuga, Mariajose, Choueiri, Toni K

“…Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity,…”
Get full text

Constant Potential and Constant Current Electrolysis: An Introduction and Comparison of Different Techniques for Organic Electrosynthesis by Rafiee, Mohammad, Mayer, Mikayla N., Punchihewa, Buwanila T., Mumau, Matthew R.

Get full text

Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial by Rini, Brian I, Prof, Melichar, Bohuslav, Prof, Ueda, Takeshi, Prof, Grünwald, Viktor, MD, Fishman, Mayer N, Prof, Arranz, José A, MD, Bair, Angel H, PhD, Pithavala, Yazdi K, PhD, Andrews, Glen I, MS, Pavlov, Dmitri, PhD, Kim, Sinil, MD, Jonasch, Eric, MD

“…Summary Background Population pharmacokinetic data suggest axitinib plasma exposure correlates with efficacy in metastatic renal-cell carcinoma. Axitinib dose…”
Get full text

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study by Powles, Thomas, O'Donnell, Peter H, Massard, Christophe, Arkenau, Hendrik-Tobias, Friedlander, Terence W, Hoimes, Christopher J, Lee, Jae Lyun, Ong, Michael, Sridhar, Srikala S, Vogelzang, Nicholas J, Fishman, Mayer N, Zhang, Jingsong, Srinivas, Sandy, Parikh, Jigar, Antal, Joyce, Jin, Xiaoping, Gupta, Ashok K, Ben, Yong, Hahn, Noah M

“…The data reported herein were accepted for assessment by the US Food and Drug Administration for Biologics License Application under priority review to…”
Get more information

Information processing in echo state networks at the edge of chaos by Boedecker, Joschka, Obst, Oliver, Lizier, Joseph T., Mayer, N. Michael, Asada, Minoru

“…We investigate information processing in randomly connected recurrent neural networks. It has been shown previously that the computational capabilities of…”
Get full text

A Single-arm, Multicenter, Phase 2 Study of Lenvatinib Plus Everolimus in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma by Hutson, Thomas E., Michaelson, M. Dror, Kuzel, Timothy M., Agarwal, Neeraj, Molina, Ana M., Hsieh, James J., Vaishampayan, Ulka N., Xie, Ran, Bapat, Urmi, Ye, Weifei, Jain, Rohit K., Fishman, Mayer N.

“…Non-clear cell renal cell carcinoma (nccRCC) accounts for ≤20% of RCC cases. Lenvatinib (a multitargeted tyrosine kinase inhibitor) in combination with…”
Get full text

Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison by Gonzalez, Brian D, Jim, Heather S L, Booth-Jones, Margaret, Small, Brent J, Sutton, Steven K, Lin, Hui-Yi, Park, Jong Y, Spiess, Philippe E, Fishman, Mayer N, Jacobsen, Paul B

“…Men receiving androgen-deprivation therapy (ADT) for prostate cancer may be at risk for cognitive impairment; however, evidence is mixed in the existing…”
Get full text

Mantle-melt Partitioning of the Highly Siderophile Elements: New Results and Application to Mars by Righter, K, II, R Rowland, Danielson, L R, Humayun, M, Yang, S, (Waeselmann), N Mayer, Pando, K

“…Trace elements and extant and extinct isotopic attributes in martian meteorites have been used to argue that Mars accreted quickly, differentiated into core…”
Get full text

The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach by Hanson, Heidi A, Martin, Christopher, O'Neil, Brock, Leiser, Claire L, Mayer, Erik N, Smith, Ken R, Lowrance, William T

“…There is a differential in prostate cancer mortality between black and white men. Advances in precision medicine have shifted the research focus toward…”
Get full text

Gender Differences in Publication Productivity among Academic Urologists in the United States by Mayer, Erik N., BS, Lenherr, Sara M., MD, MS, Hanson, Heidi A., PhD, Jessop, Terry C., BS, Lowrance, William T., MD, MPH

“…Abstract Objective To describe the publication productivity of academic urologists in the United States by gender. Materials and Methods Gender inequality is…”
Get full text

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition by Buchbinder, Elizabeth I, Dutcher, Janice P, Daniels, Gregory A, Curti, Brendan D, Patel, Sapna P, Holtan, Shernan G, Miletello, Gerald P, Fishman, Mayer N, Gonzalez, Rene, Clark, Joseph I, Richart, John M, Lao, Christopher D, Tykodi, Scott S, Silk, Ann W, McDermott, David F

“…Metastatic melanoma (mM) and renal cell carcinoma (mRCC) are often treated with anti-PD-1 based therapy, however not all patients respond and further therapies…”
Get full text

A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting by Fishman, Mayer N, Tomshine, Jin, Fulp, William J, Foreman, Pamela K

“…Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (RCC) based on the results of the pivotal phase 3 clinical trial, TARGET (Treatment…”
Get full text

Role of Spin-Orbit Coupling in High-Order Harmonic Generation Revealed by Supercycle Rydberg Trajectories by Mayer, N., Beaulieu, S., Jiménez-Galán, Á., Patchkovskii, S., Kornilov, O., Descamps, D., Petit, S., Smirnova, O., Mairesse, Y., Ivanov, M. Y.

“…High-harmonic generation is typically thought of as a sub-laser-cycle process, with the electron’sexcursion in the continuum lasting a fraction of the optical…”
Get full text

The impact of the 2020 lockdown on the psychological functioning of outpatient psychiatric patients by Grah, M, Restek-Petrović, B, Lukačić, T, Grošić, V, Milovac, Ž, Bajić, T Prga, Mayer, N

“…IntroductionThe coronavirus pandemic has led to sudden changes in the lives of people around the world. The health threat, earthquakes and epidemiological…”
Get full text

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC) by Harrison, Michael R., Costello, Brian A., Bhavsar, Nrupen A., Vaishampayan, Ulka, Pal, Sumanta K., Zakharia, Yousef, Jim, Heather S. L., Fishman, Mayer N., Molina, Ana M., Kyriakopoulos, Christos E., Tsao, Che‐Kai, Appleman, Leonard J., Gartrell, Benjamin A., Hussain, Arif, Stadler, Walter M., Agarwal, Neeraj, Pachynski, Russell K., Hutson, Thomas E., Hammers, Hans J., Ryan, Christopher W., Inman, Brant A., Mardekian, Jack, Borham, Azah, George, Daniel J.

“…Background Systemic therapy (ST) can be deferred in patients who have metastatic renal cell carcinoma (mRCC) and slow‐growing metastases. Currently, this…”
Get full text

Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial by Atkins, Michael B., Plimack, Elizabeth R., Puzanov, Igor, Fishman, Mayer N., McDermott, David F., Cho, Daniel C., Vaishampayan, Ulka, George, Saby, Tarazi, Jamal C., Duggan, William, Perini, Rodolfo, Thakur, Mahgull, Fernandez, Kathrine C., Choueiri, Toni K.

“…Axitinib plus pembrolizumab showed superior overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) versus sunitinib in a…”
Get full text

Sleep disturbance in men receiving androgen deprivation therapy for prostate cancer: The role of hot flashes and nocturia by Gonzalez, Brian D., Small, Brent J., Cases, Mallory G., Williams, Noelle L., Fishman, Mayer N., Jacobsen, Paul B., Jim, Heather S.L.

“…BACKGROUND Patients with prostate cancer receiving androgen deprivation therapy (ADT) are at risk of sleep disturbance; however, to the authors' knowledge, the…”
Get full text

Renal oncocytoma: CT features cannot reliably distinguish oncocytoma from other renal neoplasms by Choudhary, S, Rajesh, A, Mayer, N.J, Mulcahy, K.A, Haroon, A

“…Aim To retrospectively review the computed tomography (CT) imaging features of a series of histologically confirmed renal oncocytomas and to determine whether…”
Get full text